- Clone:
- REA1063 | BL168
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- ICFC Glossary
- Select a conjugate:
- Select a size:
Related products for IL-17A Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated IL-17A (REA1063) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for IL-17A. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 4 hours. Cells were stained with a suitable counterstaining and then fixed and permeabilized followed by a staining with IL-17A antibodies. As a control, IL-17A antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD3+/CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Clone REA1063 recognizes human interleukin 17A (IL-17A). IL-17A, also known as CTLA8, is a member of the IL-17 family (IL-17A–F), is a disulfide-linked homodimeric glycoprotein. IL-17A is produced by CD4+ T helper (Tʜ) cells, a third T cell subset termed Tʜ17, which secrete also cytokines such as IL-17F and IL-22 and express the natural killer (NK) cell marker CD161. IL-17A secretion has also been described for other cell types, such as CD8+ memory T cells. Furthermore, intracellular IL-17A has also been detected in eosinophils, neutrophils, and blood monocytes. Emerging data about Tʜ17 cells suggest that these cells are involved in the recruitment of neutrophils to control early stages of infections to a number of pathogens, such as extracellular bacteria and fungi. IL-17A and Tʜ17 cells have been shown to play an important role in immune-mediated diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, asthma, inflammatory bowel diseases, and other immune-mediated inflammatory conditions.
Depending on the cytokine milieu present at time of the initial engagement, CD4+ naive T cells can differentiate into various subsets (Tʜ1, Tʜ2, and Tʜ17). For the differentiation into Tʜ17 cells several cytokines have been described, including TGF-β, IL-1β, IL-6, IL-21, and IL-23. RORγt was identified as the master regulator gene for Tʜ17 cells.
Additional information: Clone REA1063 displays negligible binding to Fc receptors.
CTLA-8, IL-17
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
You have previously chosen International as your location.
What do you want to do?